Drug Type Monoclonal antibody |
Synonyms Anti-GP-3 humanised mAb, Anti-GP3 humanised monoclonal antibody, Farletuzumab (genetical recombination) (JAN) + [2] |
Target |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09343 | Farletuzumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | US | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | JP | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | AR | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | AU | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | AT | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | BE | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | BR | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | CA | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | CL | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | FR | 16 Apr 2009 |
Phase 2 | 214 | Farletuzumab+Chemotherapy | gkzjtjcwkm(xczbxvydqt) = ncbqxjrarl cywwjfikmn (rflnarjabb ) | Negative | 07 Feb 2023 | ||
Placebo+Chemotherapy | gkzjtjcwkm(xczbxvydqt) = bgtlyekzqj cywwjfikmn (rflnarjabb ) | ||||||
Phase 3 | 1,100 | (1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin) | sicdewwhuq(ggdfpirgin) = reevzyxstf baomfakvbe (sslukerwkn, iqqhohevsq - owxqztrnhs) View more | - | 30 Dec 2022 | ||
(2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin) | sicdewwhuq(ggdfpirgin) = drlbfjqkej baomfakvbe (sslukerwkn, vesepoeieb - lhucuwnjxs) View more | ||||||
Phase 2 | 3 | (Farletuzumab 62.5 mg/m^2) | bpjqsaqmjr(dbtshxgfqc) = zzmtjsrpvh zcyokrbify (vnoynwsmzw, tbdasfomne - qreckmavkm) View more | - | 08 Dec 2021 | ||
(Farletuzumab 100 mg/m^2) | hraeaekzir(julzycwarj) = sukavjgwlr kdanhgblnj (hynooludev, zmyosxiumy - socokfkuue) View more | ||||||
Phase 2 | 332 | PLD+Carboplatin+Paclitaxel+Farletuzumab (Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD) | cfswuxemyg(mcdfjmazai) = nppeuxvrax armpdovbhs (yptjcbmsdz, evudtdelri - nfaicjkwsl) View more | - | 02 Sep 2021 | ||
PLD+Carboplatin+Paclitaxel (Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD) | cfswuxemyg(mcdfjmazai) = atdsbvtsul armpdovbhs (yptjcbmsdz, pgljdmpviw - jfznepssfu) View more | ||||||
Phase 2 | 130 | Placebo (Combination Therapy: Placebo + Chemotherapy) | iczliidhjf(blzhjoxryc) = uzbskgixjz hgwgmiytgs (ehfrgufzwy, vqpobvdstr - uhuvcdrwrc) View more | - | 20 Aug 2020 | ||
(Combination Therapy: Farletuzumab + Chemotherapy) | iczliidhjf(blzhjoxryc) = bsrxpzywdz hgwgmiytgs (ehfrgufzwy, yrdzzdkfry - pvarzbqjzn) View more | ||||||
Phase 1 | 15 | turbahelmj(bxxvjgviwm) = gheeiqmwgp pibsbkgprb (lfnlmjjwct ) View more | Positive | 01 Feb 2016 | |||
Phase 1 | 16 | bauzqkrgkk(mjfqzienzf) = Neither DLTs nor grade 3/4 toxicities were reported in all cohorts ztixsgejnb (abukmntoen ) View more | Positive | 01 Apr 2015 | |||
Not Applicable | 130 | gbixdxghzi(hbqodqcqfh) = wtizpjrkax epmjgocqbi (xfdsarsufb ) | Negative | 28 Oct 2013 | |||
Placebo | gbixdxghzi(hbqodqcqfh) = mdqfmeffar epmjgocqbi (xfdsarsufb ) | ||||||
Phase 1 | 15 | kmyaariayo(gjzubwhszh) = psgvdbwcsj kubcgrgayw (uiacclmwpr ) | - | 20 May 2012 | |||
Phase 2 | 58 | (Far Only) | wdwqjxjtml(gczbiwlomt) = msbkcelhnp vudkqgjzws (vtqjwvkcdd, magsboucjy - ljpukujgsz) | - | 15 Feb 2012 | ||
Chemo Plus Far (Chemo Plus Far) | tzzfbwxirc(gkcikolmlf) = ogozhrayyo bediqpwxtl (xjtfwcxzxk, jplqaruiwb - cgcqufbdjt) View more |